NexGenix Pharmaceuticals, a privately held biotechnology company focused on developing drugs to treat the orphan-designated tumor suppressor disorder neurofibromatosis and related sporadic tumors, today announced several key personnel appointments, including the appointment of Donald D Cilla Jr, PharmD as Vice President, Clinical Development and COO; the appointment of Michelle Morin, BS to
By Phil Kabler, The Charleston Gazette, W.Va. Sep. 23--After a survey of state physicians found overwhelming support for electronic prescriptions, the consultant who headed the study urged the state Pharmaceutical Cost Management Council to go ahead with the program.
Dr. Joel H. Dobbs, Executive-in-Residence and Program Director, Pharmaceutical Management, at Stevens Institute of Technology's Howe School, will deliver the plenary keynote address, "Four Questions about Pharma's Future (and Yours)," Tues., Sept. 26, at the Drug Information Association Conference, located at the Sheraton Philadelphia City Center, Philadelphia, Penn. (Please visit http://www.
The conference brings together four groups: drug-development project management professionals, experts in outsourcing, clinical data managers and regulatory professionals who deal with global electronic product labeling.
Wal-Mart Stores Inc., long criticized for providing stingy health insurance, plans to make nearly 300 generic drugs much more affordable to its employees and customers. Post a Comment
Wal-Mart Stores Inc., long criticized for providing stingy health insurance, plans to make nearly 300 generic drugs much more affordable to its employees and customers.
Many consultants hired by businesses to find the best deals on health insurance or prescription drug plans receive "significant" bonuses, commissions or consulting fees from the companies they are hired to consider, the Wall Street Journal reports. These financial arrangements are often disclosed "only partially or not at all" to employers, the Journal reports. [click link for full article]
ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops and markets niche prescription products, announced today that it has promoted Roger Graben, Ph.D., R.Ph. to Vice President, Business Development. Dr.
TENS of thousands of pounds are being spent on complementary and alternative therapies in the NHS in Scotland - despite concerns that they do not work and are a waste of limited resources.